Sammy Farah, Turnstone Biologics CEO

The piv­ot: Turn­stone Bi­o­log­ics opens a new chap­ter with a switch to clin­i­cal de­vel­op­ment and a new ven­ture round to pay for it

In biotech, most star­tups get about 5 years to get their pre­clin­i­cal act in or­der and jump in­to hu­man stud­ies be­fore the back­ers get restive and start look­ing for the ex­its. At the 2015-found­ed Turn­stone Bi­o­log­ics, they hit that line. But in­stead of los­ing its in­vestors’ in­ter­est, it’s been pick­ing up speed and back­ers.

Now, with a lead on­colyt­ic virus in an ear­ly-stage study and a sec­ond ther­a­py from the TIL side poised for an IND, the team un­der CEO Sam­my Farah has changed the sto­ry to clin­i­cal de­vel­op­ment. And they scored an $80 mil­lion Se­ries D from a broad syn­di­cate to get this new chap­ter un­der way in style.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.